151303 20251017144615.0 doi 10.1016/j.nrl.2021.03.003 sideral 124265 ART-2021-124265 eng Caronna, E. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications [Seguridad de los anticuerpos monoclonales anti-CGRP en pacientes con migraña durante la pandemia de COVID-19: implicaciones actuales y futuras] 2021 Access copy available to the general public Unrestricted Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P = .320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19. info:eu-repo/semantics/openAccess by-nc-nd https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es 5.486 2021 CLINICAL NEUROLOGY 46 / 212 = 0.217 2021 Q1 T1 0.55 2021 Neurology (clinical) 2021 Q2 Medicine (miscellaneous) 2021 Q2 4.7 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion José Gallardo, V. Alpuente, A. Torres-Ferrus, M. Sánchez-Mateo, N.M. Viguera-Romero, J. López-Veloso, A.C. López-Bravo, A. Gago-Veiga, A.B. Irimia Sieira, P. Porta-Etessam, J. Santos-Lasaosa, S. Universidad de Zaragoza (orcid)0000-0001-5139-6031 Pozo-Rosich, P. Spanish, CGRP-COVID, Study, Group 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 36 (2021), 611-617 Neurología (Barc.) Neurología (Barcelona) 0213-4853 274672 http://zaguan.unizar.es/record/151303/files/texto_completo.pdf Versión publicada 2058833 http://zaguan.unizar.es/record/151303/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:151303 articulos driver 2025-10-17-14:19:08 ARTICLE